| Bioactivity | Bevenopran is a peripheral μ-opioid receptor antagonist[1][2]. | ||||||||||||
| Target | μ-opioid receptor | ||||||||||||
| In Vivo | Bevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD)[1]. Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1]. | ||||||||||||
| Name | Bevenopran | ||||||||||||
| CAS | 676500-67-7 | ||||||||||||
| Formula | C20H26N4O4 | ||||||||||||
| Molar Mass | 386.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Diego L, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. [2]. Siemens W, et al. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. Expert Opin Pharmacother. 2015 Mar;16(4):515-32. |